MicroRNA-based therapies that target cardiomyocyte proliferation have great potential for
the treatment of myocardial infarction. In previous work, we showed that the miR-302/367 …

A major challenge in myocardial infarction (MI)-related heart failure treatment using
microRNA is the efficient and sustainable delivery of miRNAs into myocardium to achieve …

Rationale: Recent evidence indicates that a few human microRNAs (miRNAs), in particular
hsa-miR-199a-3p and hsa-miR-590-3p, stimulate proliferation of cardiomyocytes and, once …

MicroRNA-based therapy that targets cardiac macrophages holds great potential for
treatment of myocardial infarction (MI). Here, we explored whether boosting the miRNA-21 …

In contrast to lower vertebrates, the mammalian heart has limited capacity to regenerate after
injury in part due to ineffective reactivation of cardiomyocyte proliferation. We show that the …

Background—Cell therapy with bone marrow–derived mononuclear cells (BMCs) can
improve recovery of cardiac function after ischemia; however, the molecular mechanisms …

MicroRNA-144 is a cytoprotective miRNA. Our previous study showed that miR-144 provides
potent acute cardioprotection in an ischemia/reperfusion injury model. This study was …

Rationale: Clinical application of mesenchymal stem cells (MSCs) and MSC-derived
exosomes (MSC-Exos) to alleviate myocardial ischemia/reperfusion (I/R) injury is …

In mammals, enlargement of the heart during embryonic development is primarily
dependent on the increase in cardiomyocyte numbers. Shortly after birth, however …

Rationale: A major goal for the treatment of heart tissue damaged by cardiac injury is to
develop strategies for restoring healthy heart muscle through the regeneration and repair of …